GLP1R and type 2 diabetes mellitus: Whereas SGLT2 inhibitors are preferable over GLP-1 receptor agonists in heart failure with or without T2DM due to results from specific heart failure trials and current guideline recommendations, our analysis could not identify a greater advantage for either drug class regarding composite renal outcomes.